Category: CovidienSyndicate content

Dr. Tom Fogarty: Venture capital is dead and it's starting to stink

November 10, 2014 by Brian Johnson

The director of the Fogarty Institute, medtech legend Dr. Tom Fogarty, shoots off some fireworks at MassMEDIC's 18th annual Medtech Showcase.

Dr. Tom Fogarty: Venture is dead and it's starting to stink

In the 50 years since Dr. Tom Fogarty invented the catheter-based treatment for blood clots that's now the standard of care, he's founded more than 30 medical device startups, placing him among the most prolific inventors in the biomedical space.

Forgarty is also, without a doubt, the industry's best quote.

Medtronic inks $16B loan package for Covidien buyout

November 10, 2014 by Brad Perriello

Medtronic inks a package of loans worth more than $16 billion to back its $43 billion acquisition of Covidien.

Medtronic inks $16B loan package for Covidien buyout

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Class I recall for Covidien's Puritan 980 ventilator

November 10, 2014 by Brad Perriello

Covidien's recall of its Puritan 980 ventilator over a software glitch earns Class I status from the FDA, the watchdog agency's highest-level alert.

Class I recall for Covidien's Puritan 980 ventilator

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

The silver lining for healthcare in U.S. inversion rules

November 6, 2014 by MassDevice

Instead of quashing mergers and acquisitions altogether, the U.S. Treasury Dept.'s proposal on tax inversions may pull dealmaking onshore.

Healthcare sector sees silver lining in U.S. tax inversion rules

(Reuters) - Investors and bankers have been lamenting the potential death of large cross-border healthcare mergers since the U.S. Treasury Dept. announced in late September that it would curtail the tax breaks from international deals designed to give U.S. companies a legal home in a low-tax country.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Atherectomy and balloon angioplasty beat angioplasty alone in Covidien trial

November 6, 2014 by Val Kennedy

Atherectomy and balloon angioplasty proves more effective than angioplasty alone in treating peripheral artery disease, according to new data from a Covidien study.

Atherectomy and balloon angioplasty beat angioplasty alone in Covidien trial

Plan for Medtronic-Covidien management structure unveiled | The week in medtech M&A

November 5, 2014 by MassDevice

Here's a look at some of the top mergers & acquisitions stories for medical device companies this week: Medtronic unveils post-merger management structure; Abbott buys into electrophysiology with $250m Topera acquisition; Zimmer reveals post-Biomet merger plans; Medtronic, Covidien merger expected to close in 2015; Covidien deals Stellarex balloon to Spectranetics for $30m

Medtronic unveils post-merger management structure

October 30, 2014 by Val Kennedy

Covidien beats with fiscal Q4, 2014 results

November 5, 2014 by Brad Perriello

Covidien's fiscal 4th-quarter and 2014 earnings top expectations on Wall Street as 4th-quarter profits soar 39%.

Covidien beats with fiscal Q4, 2014 results

Covidien (NYSE:COV) handily beat analysts' expectations for its fiscal 4th-quarter and full-year results this morning, topping earnings-per-share forecasts with Q4 profit growth of 39%.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp